XML 100 R65.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue and segmental reporting, Collaboration (Details)
$ in Millions
 1 Months Ended 12 Months Ended
Nov. 30, 2018
USD ($)
Jul. 31, 2014
USD ($)
Target
Dec. 31, 2020
GBP (£)
Target
Program
Dec. 31, 2019
GBP (£)
Program
Dec. 31, 2018
GBP (£)
Mar. 31, 2021
GBP (£)
Nov. 30, 2018
GBP (£)
Nov. 30, 2018
USD ($)
Collaboration [Abstract]                
Total deferred revenue     £ 51,986,000 £ 76,418,000        
Research and development costs     74,809,000 99,991,000 £ 83,575,000      
Deferred revenue held in current liabilities     27,118,000 28,457,000        
Increased revenue recognized     5,027,000          
Genentech [Member]                
Collaboration [Abstract]                
Aggregate Non-refundable fee payment | $               $ 100
Initial upfront payment | $ $ 50              
Amount on investigation of new drug filing for clinical trial | $ $ 50              
Total deferred revenue             £ 77,400,000 $ 100
Revenue recognized     20,236,000 19,097,000 1,461,000      
Research and development costs     £ 2,785,000 1,696,000      
Genentech [Member] | Bottom of Range [Member]                
Collaboration [Abstract]                
Estimated period of performance obligation would be satisfied     2 years          
Genentech [Member] | Top of Range [Member]                
Collaboration [Abstract]                
Estimated period of performance obligation would be satisfied     3 years          
GlaxoSmithKline [Member]                
Collaboration [Abstract]                
Aggregate Non-refundable fee payment     £ 22,900,000          
Total deferred revenue     1,955,000          
Revenue recognized     6,356,000 5,753,000 6,079,000      
Research and development costs     2,897,000 2,159,000      
Non-refundable payment received     £ 0 0        
Number of remaining target | Target     2          
GlaxoSmithKline [Member] | Subsequent Events [Member]                
Collaboration [Abstract]                
Target amount for release of deferred income           £ 3,208,000    
GlaxoSmithKline [Member] | Bottom of Range [Member]                
Collaboration [Abstract]                
Remaining target timeframes     1 year          
GlaxoSmithKline [Member] | Top of Range [Member]                
Collaboration [Abstract]                
Number of target | Target     4          
Remaining target timeframes     2 years          
Eli Lilly [Member]                
Collaboration [Abstract]                
Aggregate Non-refundable fee payment | $   $ 45            
Total deferred revenue   $ 45   3,132,000        
Revenue recognized     £ 3,522,000 £ 819,000 8,561,000      
Number of target | Target   3            
Number of termination of programs | Program       1        
Deferred revenue held in current liabilities     £ 7,361,000          
Number of remaining programs | Program     2          
Increased revenue recognized     £ 705,000          
Eli Lilly [Member] | Bottom of Range [Member]                
Collaboration [Abstract]                
Contribution percentage on research and development cost   25.00%            
Eli Lilly [Member] | Top of Range [Member]                
Collaboration [Abstract]                
Contribution percentage on research and development cost   50.00%            
Med Immune [Member]                
Collaboration [Abstract]                
Revenue recognized         £ 7,553,000